Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference
Calliditas Therapeutics AB (Nasdaq: CALT) CEO Renée Aguiar-Lucander will participate in the 2024 Women in Nephrology (WIN) Leadership Conference in Los Angeles on August 9-10. She will join a panel titled 'How to be Efficient as a Leader in Academia and Industry', focusing on female representation and leadership in the nephrology field.
Aguiar-Lucander emphasizes the progress of women in industry leadership but acknowledges that more work is needed. She highlights the importance of celebrating female leaders' successes and improving mentorship to drive innovation, growth, and profitability. The CEO will share her experience in management, building successful organizations, and the impact of women in leadership at Calliditas.
WIN, founded in 1983, aims to provide mentorship and guidance to all nephrologists and scientists, particularly those historically underrepresented in the field.
Calliditas Therapeutics AB (Nasdaq: CALT) il CEO Renée Aguiar-Lucander parteciperà alla Leadership Conference 2024 delle Donne in Nefrologia (WIN) a Los Angeles il 9-10 agosto. Parteciperà a un pannello intitolato 'Come essere Efficaci come Leader nell'Accademia e nell'Industria', concentrandosi sulla rappresentanza femminile e sulla leadership nel campo della nefrologia.
Aguiar-Lucander sottolinea i progressi delle donne nella leadership industriale, ma riconosce che c'è ancora molto lavoro da fare. Sottolinea l'importanza di celebrare i successi delle leader femminili e di migliorare il mentoring per promuovere innovazione, crescita e profittabilità. Il CEO condividerà la sua esperienza nella gestione, nella creazione di organizzazioni di successo e l'impatto delle donne nella leadership in Calliditas.
WIN, fondata nel 1983, ha l'obiettivo di fornire mentorship e guida a tutti i nefrologi e scienziati, in particolare a quelli storicamente sotto-rappresentati nel settore.
Calliditas Therapeutics AB (Nasdaq: CALT) la CEO Renée Aguiar-Lucander participará en la Conferencia de Liderazgo 2024 de Mujeres en Nefrología (WIN) en Los Ángeles los días 9 y 10 de agosto. Se unirá a un panel titulado 'Cómo ser Eficiente como Líder en la Academia y la Industria', centrado en la representación femenina y el liderazgo en el campo de la nefrología.
Aguiar-Lucander enfatiza el progreso de las mujeres en liderazgo industrial, pero reconoce que se necesita hacer más. Destaca la importancia de celebrar los éxitos de las líderes femeninas y mejorar el mentoría para impulsar la innovación, el crecimiento y la rentabilidad. La CEO compartirá su experiencia en gestión, construcción de organizaciones exitosas y el impacto de las mujeres en el liderazgo en Calliditas.
WIN, fundada en 1983, tiene como objetivo proporcionar mentoría y orientación a todos los nefrologos y científicos, particularmente a aquellos históricamente subrepresentados en el campo.
Calliditas Therapeutics AB (Nasdaq: CALT)의 CEO인 Renée Aguiar-Lucander는 8월 9일부터 10일까지 로스앤젤레스에서 열리는 2024 여성 신장병학(WIN) 리더십 컨퍼런스에 참석할 것입니다. 그녀는 '학계와 산업에서 리더로서의 효율성을 높이는 방법'이라는 제목의 패널에 참여하여 신장병학 분야의 여성 대표성과 리더십에 대해 논의할 예정입니다.
Aguiar-Lucander는 산업 리더십에서 여성의 진전을 강조하지만 더 많은 노력이 필요하다고 인정합니다. 그녀는 여성 리더들의 성공을 축하하고 멘토십을 개선하여 혁신, 성장 및 수익성을 촉진하는 것이 중요하다고 강조합니다. CEO는 경영 경험, 성공적인 조직 구축 및 Calliditas에서의 여성 리더십의 영향에 대해 공유할 것입니다.
WIN은 1983년에 설립되어 모든 신장병 전문의와 과학자들에게 멘토십과 지침을 제공하는 것을 목표로 하며, 특히 역사적으로 이 분야에서 과소대표된 이들을 지원합니다.
Calliditas Therapeutics AB (Nasdaq: CALT) la PDG Renée Aguiar-Lucander participera à la Conférence de Leadership 2024 des Femmes en Néphrologie (WIN) à Los Angeles les 9 et 10 août. Elle rejoindra un panel intitulé 'Comment Etre Efficace en Tant que Leader dans l'Académie et l'Industrie', axé sur la représentation et le leadership féminin dans le domaine de la néphrologie.
Aguiar-Lucander souligne les progrès des femmes dans le leadership industriel, mais reconnaît qu'il y a encore du travail à faire. Elle met en avant l'importance de célébrer les succès des femmes leaders et d'améliorer le mentorat pour favoriser l'innovation, la croissance et la rentabilité. La PDG partagera son expérience en management, la construction d'organisations prospères et l'impact des femmes dans le leadership chez Calliditas.
WIN, fondée en 1983, a pour objectif de fournir mentorat et soutien à tous les néphrologues et scientifiques, en particulier à ceux historiquement sous-représentés dans le domaine.
Calliditas Therapeutics AB (Nasdaq: CALT) CEO Renée Aguiar-Lucander wird am 9. und 10. August an der 2024 Women in Nephrology (WIN) Leadership Conference in Los Angeles teilnehmen. Sie wird an einem Panel mit dem Titel 'Wie man als Führungskraft in der Akademie und Industrie effizient ist' teilnehmen, das sich auf die weibliche Vertretung und Führung im Bereich der Nephrologie konzentriert.
Aguiar-Lucander hebt den Fortschritt von Frauen in Führungspositionen in der Industrie hervor, erkennt jedoch an, dass noch mehr Arbeit erforderlich ist. Sie betont die Bedeutung, die Erfolge von weiblichen Führungskräften zu feiern und das Mentoring zu verbessern, um Innovation, Wachstum und Rentabilität voranzutreiben. Die CEO wird ihre Erfahrungen im Management, beim Aufbau erfolgreicher Organisationen und den Einfluss von Frauen in Führungspositionen bei Calliditas teilen.
WIN wurde 1983 gegründet und hat das Ziel, allen Nefrologen und Wissenschaftlern, insbesondere den historisch unterrepräsentierten Personen im Bereich, Mentoring und Unterstützung zu bieten.
- None.
- None.
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT) (“Calliditas”) Chief Executive Officer, Renée Aguiar-Lucander, will participate in a panel during this year’s Women in Nephrology (WIN) Leadership Conference in Los Angeles, CA on August 9 – 10.
The panel, titled “How to be Efficient as a Leader in Academia and Industry,” will focus on the importance of female representation and leadership. On that topic, Aguiar-Lucander notes, “I believe women in the industry have made great strides in terms of leadership positions but there is clearly still significant work to do. The industry remains male-dominated and closed networks still exist. It’s therefore important to shine a light on all of the success that female leaders have achieved and how diversity and a variety of leadership styles continue to successfully drive innovation, growth and profitability. We should publicize and celebrate this positive change whilst improving mentorship and support all of the amazing women in our organizations. If we can do that, I’m hopeful that more women will rise to the top and excel at whatever they set their minds to.”
WIN was founded in 1983 by women in the nephrology field who had a goal of developing and providing mentorship and guidance to all nephrologists and scientists, including those that historically have been under-represented. In alignment with this goal, Aguiar-Lucander will be speaking to her experience in management, the art of building a winning organization as CEO, and the specific impact of the women in leadership at Calliditas.
For more information about this conference, visit the Women in Nephrology website here.
About Calliditas
Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in rare diseases with significant unmet medical needs. Calliditas’ common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT). Visit Calliditas.com for further information.
For further information, please contact:
Emma Santos
egsantos@lifescicomms.com
FAQ
When and where is Calliditas Therapeutics (CALT) participating in the Women in Nephrology Leadership Conference?
What panel will Calliditas Therapeutics' CEO be speaking on at the 2024 WIN conference?
What topics will Renée Aguiar-Lucander discuss at the 2024 Women in Nephrology conference?
What is the goal of the Women in Nephrology (WIN) organization?
